Gregg Williams, a director and 10% owner of Vivani Medical, Inc. (NASDAQ:VANI), purchased 793,650 shares of the company’s common stock for a total value of $999,999. The transaction occurred on July 15, 2026, with shares acquired at a price of $1.26 each.
This acquisition was a private sale transaction, as detailed in a Share Purchase Agreement dated August 11, 2025. The price of $1.26 per share matched the last reported sale price of Vivani Medical’s common stock on the Nasdaq on August 10, 2025, the day immediately preceding the agreement date.
Following this purchase, Mr. Williams holds a total of 41,711,936 shares of Vivani Medical common stock. The stock currently trades at $1.41, up from the $1.26 purchase price, though it has declined roughly 10% over the past week. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value estimate, even as analysts maintain price targets between $3.50 and $4.00. InvestingPro offers 10 additional exclusive tips and comprehensive financial metrics for VANI investors. These holdings include 4,799,200 shares owned directly by Mr. Williams. The remaining shares are held indirectly through various entities, including 34,786,984 shares by the Gregg G. Williams 2006 Trust, 1,212,856 shares by Williams International Co. LLC, 181,587 shares by Sam Williams Family Investments LLC, and 731,309 shares by Sam B. Williams 1995 Generation-Skipping Trust. Mr. Williams maintains voting and dispositive power over all these shares.
In other recent news, Vivani Medical, Inc. announced its agreement with Novo Nordisk to evaluate NPM-139, a semaglutide drug implant developed for chronic weight management. This agreement does not include exclusivity provisions for NPM-139 or Vivani’s NanoPortal platform technology. Additionally, Vivani Medical revealed it received approval from Bellberry in Australia to commence the SLIM-1 Phase 1 clinical trial of the semaglutide implant in mid-2026. The trial will compare a low-dose NPM-139 with Wegovy in obese or overweight subjects.
In a significant corporate development, Vivani Medical also entered into a merger agreement involving its subsidiary Cortigent Inc and ClearOne Inc. As a result, Vivani will acquire 12,500,000 shares of ClearOne common stock. In terms of company leadership, Vivani Medical appointed August Moretti to its board of directors, succeeding Dr. Dean Baker, who retired. Moretti will chair the Audit Committee and serve on the Compensation Committee.
On the analyst front, H.C. Wainwright reiterated a Buy rating on Vivani Medical with a price target of $3.50 following the Novo Nordisk agreement. Furthermore, Lake Street initiated coverage on Vivani Medical with a Buy rating and a price target of $4.00, emphasizing the company’s implant technology for long-term medication delivery. These developments reflect Vivani Medical’s strategic moves and ongoing advancements in its medical technology initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
investment News
